

FIG. 1A




FIG. 1B

Description	PLACEBO (N=29)	Conjugate A 50 mg (N=2)	Conjugate A 150 mg (N=28)	All (N=59)
Randomized participants	29 (100.0)	2 (100.0)	28 (100.0)	59 (100.0)
Participants receiving treatment	29 (100.0)	2 (100.0)	28 (100.0)	59 (100.0)
Participants receiving challenge virus	28 (96.6)	2 (100.0)	28 (100.0)	58 (98.3)

FIG. 2

Description	Statistics	PLACEBO (N=28)	Conjugate A 50 mg (N=28)
Sex	N	28	28
	Missing	0	0
Male	n (%)	20 (71.4)	15 (53.6)
Female	n (%)	8 (28.6)	13 (46.4)
Age	N	28	28
	Missing	0	0
	Mean	33.32	33.82
	S.D	8.21	7.86
	Median	32.00	32.00
	Q1, Q3	28.00, 37.50	28.50, 38.50
	Min, Max	22.0, 51.0	21.0, 51.0
Ethnicity	N	28	28
	Missing	0	0
Hispanic / Latino	n (%)	0 (0.0)	0 (0.0)
Not Hispanic / Latino	n (%)	28 (100.0)	28 (100.0)
Weight (kg)	N	28	28
	Missing	0	0
	Mean	76.60	79.66
	S.D	13.40	18.98
	Median	72.95	75.60
	Q1, Q3	66.75, 87.95	63.10, 90.85
	Min, Max	54.2, 100.8	54.2, 111.4

FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10






FIG. 12





FIG. 13






FIG. 15




FIG. 16




FIG. 17

